EUVIMEDEUVIMED entdecken
Crossref

Targeted Therapy for Oral Squamous Cell Carcinoma: Emerging Therapeutic Strategies and Clinical Perspectives

Praveen S. Anigol, Vijayalakshmi Kotrashetti, Kishore G. Bhat, Bhagyashri N. Vanaki

International Journal of Current Pharmaceutical Review and Research · 31.03.2026 · 18 (03)

DOI: 10.25258/ijcpr.18.3.197 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 31.03.2026. Verfasst von Praveen S. Anigol und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral squamous cell carcinoma (OSCC) represents a significant global health burden with limited therapeutic options beyond conventional surgery, radiotherapy, and chemotherapy. The molecular characterization of OSCC has revealed numerous dysregulated signaling pathways, providing opportunities for targeted therapeutic intervention. This review comprehensively examines emerging targeted therapies for OSCC, focusing on novel agents and their molecular mechanisms. Epidermal growth factor receptor (EGFR) inhibitors, including cetuximab, gefitinib, and erlotinib, have demonstrated clinical efficacy, with cetuximab showing improved overall survival when combined with radiotherapy or chemotherapy. Immune checkpoint inhibitors targeting PD-1/PDL1, such as pembrolizumab and nivolumab, have revolutionized treatment paradigms for recurrent or metastatic disease. The PI3K/AKT/mTOR pathway represents another promising target, with multiple inhibitors under investigation. MEK inhibitors like trametinib have shown encouraging results in neoadjuvant settings, achieving significant tumor responses. Novel targets including STAT3, VEGFR, dual tyrosine kinase inhibitors, and epigenetic modulators are emerging as potential therapeutic options. Despite these advances, challenges remain, including primary and acquired resistance, tumor heterogeneity, limited biomarker validation, and the need for personalized treatment strategies. Clinical trials have demonstrated variable response rates and modest survival benefits, highlighting the complexity of OSCC biology. Future directions include combination therapies, identification of predictive biomarkers, development of novel delivery systems, and integration of multi-omics approaches for patient stratification. This review synthesizes current evidence on emerging targeted therapies, providing insights into molecular mechanisms, clinical outcomes, and future research priorities for improving OSCC patient outcomes.

Zitieren

APA

Anigol, P. S., Kotrashetti, V., Bhat, K. G., & Vanaki, B. N. (2026). Targeted Therapy for Oral Squamous Cell Carcinoma: Emerging Therapeutic Strategies and Clinical Perspectives. International Journal of Current Pharmaceutical Review and Research, 18(03). https://doi.org/10.25258/ijcpr.18.3.197

Vancouver

Anigol PS, Kotrashetti V, Bhat KG, Vanaki BN. Targeted Therapy for Oral Squamous Cell Carcinoma: Emerging Therapeutic Strategies and Clinical Perspectives. International Journal of Current Pharmaceutical Review and Research. 2026;18(03). doi:10.25258/ijcpr.18.3.197

BibTeX
@article{Anigol2026,
  author = {Anigol, Praveen S. and Kotrashetti, Vijayalakshmi and Bhat, Kishore G. and Vanaki, Bhagyashri N.},
  title = {Targeted Therapy for Oral Squamous Cell Carcinoma: Emerging Therapeutic Strategies and Clinical Perspectives},
  journal = {International Journal of Current Pharmaceutical Review and Research},
  year = {2026},
  volume = {18},
  number = {03},
  doi = {10.25258/ijcpr.18.3.197}
}
Kostenlos starten →